Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 5
1984 1
1985 4
1986 1
1987 4
1988 7
1989 6
1990 3
1991 7
1992 4
1993 10
1994 5
1995 7
1996 21
1997 8
1998 3
1999 8
2000 11
2001 11
2002 7
2003 26
2004 23
2005 19
2006 13
2007 24
2008 17
2009 15
2010 18
2011 11
2012 15
2013 14
2014 13
2015 10
2016 11
2017 15
2018 9
2019 8
2020 7
2021 6
2022 4
2023 6
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

397 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Motzer RJ, et al. N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406148 Free PMC article. Clinical Trial.
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Choueiri TK, et al. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25. N Engl J Med. 2015. PMID: 26406150 Free PMC article. Clinical Trial.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. Among authors: figlin ra. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Free article. Clinical Trial.
Targeting Glutamine Metabolism in Prostate Cancer.
Bhowmick N, Posadas E, Ellis L, Freedland SJ, Vizio DD, Freeman MR, Theodorescu D, Figlin R, Gong J. Bhowmick N, et al. Among authors: figlin r. Front Biosci (Elite Ed). 2023 Jan 4;15(1):2. doi: 10.31083/j.fbe1501002. Front Biosci (Elite Ed). 2023. PMID: 36959101 Free article. Review.
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study.
Choueiri TK, McDermott DF, Merchan J, Bauer TM, Figlin R, Heath EI, Michaelson MD, Arrowsmith E, D'Souza A, Zhao S, Roy A, Perini R, Vickery D, Tykodi SS. Choueiri TK, et al. Among authors: figlin r. Lancet Oncol. 2023 May;24(5):553-562. doi: 10.1016/S1470-2045(23)00097-9. Epub 2023 Mar 31. Lancet Oncol. 2023. PMID: 37011650 Clinical Trial.
Renal cell cancer.
Hutson TE, Figlin RA. Hutson TE, et al. Among authors: figlin ra. Cancer J. 2007 Sep-Oct;13(5):282-6. doi: 10.1097/PPO.0b013e318156fe69. Cancer J. 2007. PMID: 17921725 Review.
Genetic and biological drivers of prostate cancer disparities in Black men.
Gong J, Kim DM, Freeman MR, Kim H, Ellis L, Smith B, Theodorescu D, Posadas E, Figlin R, Bhowmick N, Freedland SJ. Gong J, et al. Among authors: figlin r. Nat Rev Urol. 2024 May;21(5):274-289. doi: 10.1038/s41585-023-00828-w. Epub 2023 Nov 14. Nat Rev Urol. 2024. PMID: 37964070 Review.
Targeted therapies for renal cell carcinoma.
Posadas EM, Limvorasak S, Figlin RA. Posadas EM, et al. Among authors: figlin ra. Nat Rev Nephrol. 2017 Aug;13(8):496-511. doi: 10.1038/nrneph.2017.82. Epub 2017 Jul 10. Nat Rev Nephrol. 2017. PMID: 28691713 Review.
397 results